Income Tax Expense (Benefit) of ZyVersa Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: ZyVersa Therapeutics, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 30 Sep 2022 to 30 Sep 2025.
ZyVersa Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $851,659.
ZyVersa Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $6,745.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Change (%)

Income Tax Expense (Benefit), Annual (USD)

ZyVersa Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025		$851,659			01 Jul 2025	30 Sep 2025	10-Q	19 Nov 2025	2025	Q3
Q2 2024		$9,707	+$7,821,933		01 Apr 2024	30 Jun 2024	10-Q	13 Aug 2025	2025	Q2
Q4 2023	$9,455,830	$596,068	+$148,982	+20%	01 Oct 2023	31 Dec 2023	10-K	27 Mar 2025	2024	FY
Q3 2023	$9,604,812	$485^*	-$48,036		01 Jul 2023	30 Sep 2023	10-Q	14 Nov 2024	2024	Q3
Q2 2023	$9,556,776	$7,812,226			01 Apr 2023	30 Jun 2023	10-Q	09 Aug 2024	2024	Q2
Q1 2023		$1,047,051			01 Jan 2023	31 Mar 2023	10-Q	15 May 2024	2024	Q1
Q4 2022		$745,050			13 Dec 2022	31 Dec 2022	10-K	25 Mar 2024	2023	FY
Q3 2022		$47,551			01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2022	2022	Q3

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$6,745	+$9,462,575		01 Jan 2024	31 Dec 2024	10-K	27 Mar 2025	2024	FY
2023	$9,455,830			01 Jan 2023	31 Dec 2023	10-K	27 Mar 2025	2024	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.